Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
South China Univ. of Technology XOR/URAT1 compound I7: sourced facts only. name: "I7 showed the best inhibitory effect on XOR (IC50 = 0.037 ± 0.001 μM) and URAT1 (IC50 = 546.70 ± 32.60 μM)."; target: "I7 showed the best inhibitory effect on XOR (IC50 = 0.037 ± 0.001 μM) and URAT1 (IC50 = 546.70 ± 32.60 μM)."; target: "I7 showed the best inhibitory effect on XOR (IC50 = 0.037 ± 0.001 μM) and URAT1 (IC50 = 546.70 ± 32.60 μM)."; developer: "MOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China."
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on South China Univ. of Technology XOR/URAT1 compound I7.
Work on South China Univ. of Technology XOR/URAT1 compound I7? Claim this page to correct or add information. Claim this page